Skip to main content
OpenTrials
Completed

NCT Number: NCT02304874

Evaluation of Body Iron Stores in Overweight Healthy Volunteers

Normal body iron store value in overweight subjects is currently not described in literature. The comparison of this value with body iron levels in patients suffering from dysmetabolic iron overload syndrome (DIOS) could allow to quantify iron overload in this condition. The purpose of the study is to determine iron levels in healthy overweight volunteers, and to compare them to DIOS patients treated with phlebotomy.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Normal body iron store value in overweight subjects is currently not described in literature. The comparison of this value with body iron levels in patients suffering from dysmetabolic iron overload syndrome (DIOS) could allow to quantify iron overload in this condition.

DIOS is the leading cause of hyperferritinemia and mainly affects men between 45 and 60 years. It is characterized by unexplained hyperferritinemia associated to metabolic disorders (including overweight) and iron overload, objectified by MRI or liver biopsy.

Some authors suggest that hyperferritinemia associated to metabolic disorders is the expression of an inflammatory syndrome caused by insulin resistance and steatohepatitis, and not the manifestation of real iron overload.

The debate surrounding iron overload in DIOS is related to the limits of the current analysis methods (phlebotomy, liver iron concentration, MRI). At present, phlebotomy is the standard method used to determine body iron stores.

Using this method, the purpose of the study is to determine iron levels in healthy overweight volunteers, and to compare them to DIOS patients treated with phlebotomy included in another ongoing clinical trial (SAIGNEES - ClinicalTrials.gov Identifier: NCT01045525).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male,
  • At least 18 years old
  • BMI > 25 Kg/m2
  • Serum ferritin level between 100 et 300 µg/L
  • Written informed consent

Exclusion criteria

  • Blood donations in the past two years
  • Alcohol consumption more than 30 g/day
  • Inflammatory syndrome (CRP > 10 mg/L)
  • Inflammatory, dysimmunitary or cancerous disease
  • Hepatic cytolysis
  • Transferrin saturation > 45%
  • Person involved in another clinical trial
  • Person with a measure of legal protection (guardianship)
  • Person who reached the annual limit for compensation provided by biomedical research
  • Hemoglobin < 13 g/dL
  • Uncontrolled heart failure or coronary insufficiency
  • Abnormal ECG
  • Echocardiographic abnormalities contraindicating phlebotomy
  • Hepatic, renal or respiratory insufficiency
  • Superficial venous network insufficiency

Treatment and study plan

Phlebotomy

Other

Primary outcomes

  1. Amount of mobilized iron (AMI) in grams collected by phlebotomies to have a ferritin level < 50 µg/L

    Time frame: Every 14 days, up to 3 months

    Phlebotomies will be performed every 14 days at the Clinical Investigation Unit, until ferritin level is below 50 µg/mL and/or hemoglobin is below 12 g/dL.

Secondary outcomes

  1. Serum hepcidin level variation during the phlebotomy

    Time frame: Every 14 days, up to 3 months

  2. Serum soluble transferrin receptor variation during the phlebotomy

    Time frame: Every 14 days, up to 3 months

Sponsors and collaborators

Lead sponsor

Rennes University Hospital

Other

Registry information

Acronym: FERNORM

Important dates

Study start
2011
Primary completion
2013
Study completion
2014
First posted
Dec 2, 2014
Registry last updated
May 24, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.